CAR T-cell therapy for advanced B-cell Non-Hodgkin Lymphoma





Providence Cancer Institute is one of the few highly specialized centers offering adoptive cellular therapy for hematologic malignancies. Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular therapy approved for certain types of leukemia and lymphoma. A new phase II study will evaluate an investigational CAR T-cell therapy for patients with advanced B-cell Non-Hodgkin Lymphoma (NHL).

View the study here:

A Phase 2, Open-label, Single Arm, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 (Lisocabtagene Maraleucel) in Adult Subjects With High-risk, Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This global, open-label study will assess the safety and effectiveness of lisocabtagene maraleucel (liso-cel) as second- or third-line treatment in adult patients with high-risk, relapsed or refractory indolent B-cell NHL.

Liso-cel consists of genetically engineered CD8+ and CD4+ autologous T lymphocytes directed against CD19, a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The agent also contains a 4-1BB costimulatory domain to enhance proliferation of T cells and antitumor activity. A prior study found a high response rate in patients with relapsed or refractory large B-cell lymphomas who received liso-cel.

John Godwin, M.D., MS, medical oncologist and program leader of hematologic malignancies, is a principal investigator of the study. Eligible patients will receive lymphodepleting chemotherapy followed by infusion of CD8+ and CD4+ CAR T cells.

For more information or to refer patients to this study, please call our Clinical Research office at 503-215-2614 or submit a referral form.

More hematologic studies

More than 20 clinical trials are open at Providence Cancer Institute for patients with hematologic cancers. See all hematology studies.

New research studies are added frequently. Please visit our website to see all studies in all cancer types at Providence Cancer Institute.

Leaders in cellular therapy

Adoptive cellular therapy is very effective in treating certain cancers, and we believe that it holds the potential to treat any cancer. Unlocking its potential is one of our major research priorities. Under the leadership of Eric Tran, Ph.D., an NCI-trained expert in T-cell therapy, our research team continues to explore new avenues in adoptive cellular therapy. Currently, we are:

  • Collaborating with our molecular genomics team to identify the unique mutations expressed by tumors, as well as the T cells that can recognize those genetic mutations
  • Developing programs to generate personalized, potent and precise T-cell therapies in our own labs to target an individual’s unique cancer cells

To learn more, visit Providence Hematologic Malignancies Program.

Previous Article
COVID-19 response: How Providence Southwest Washington continues to serve our Mission
COVID-19 response: How Providence Southwest Washington continues to serve our Mission

Next Article
COVID scared to cancer aware
COVID scared to cancer aware

Sue Jones was afraid to come to the hospital for routine, diagnostic tests — like her mammogram. Despite he...